A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières Syndrome (AGS).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must be diagnosed with genetic diagnosis of NNS/CANDLE, SAVI, or AGS
Participants with NNS/CANDLE and SAVI must be 17.5 months of age, AGS must be 6 months of age
Participants must be 5kg in body weight
Participants Must Not:
Participants must not be pregnant or breastfeeding
Participant must not have active tuberculosis (TB)
Participant must not have cancer
Participants must not have any history of blood clot within 12 weeks before entering study
Participants must not have ever participated in any other clinical trials using baricitinib
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo